Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Breast
12:22

2024 SABCS Annual Meeting Insights Hub

SABCS 2024 Summary: Next-Generation SERDs and Their Clinical Applications in ER+ Breast Cancer

FEATURING Rinath Jeselsohn
  • 5 views
  • January 14, 2025
14:52

2024 SABCS Annual Meeting Insights Hub

SABCS 2024 Summary: Evolution of SERDs - Limitations of Fulvestrant and the Need for New Oral Therapies in ER+ Breast Cancer

FEATURING Rinath Jeselsohn
  • January 13, 2025
07:58

2024 SABCS Annual Meeting Insights Hub

SABCS 2024 Insights: Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemo in Young Patients With eBC

FEATURING Megan Tesch
  • 71 views
  • December 17, 2024
  • 2
01:56

2024 SABCS Annual Meeting Insights Hub

SABCS 2024 Insights: Valemetostat + T-DXd in Previously Treated, Unresectable or Metastatic HER2-Low Breast Cancer

FEATURING Sara Tolaney
  • 6 views
  • December 17, 2024
02:18

2024 SABCS Annual Meeting Insights Hub

SABCS 2024 Insights: EmpowHER 303 - Zanidatamab vs. Trastuzumab + Chemo in HER2+ mBC Post-T-DXd

FEATURING Sara Tolaney
  • 11 views
  • December 17, 2024
02:25

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Quantitative High Sensitivity HER2 Testing With Trastuzumab Deruxtecan in mBC

FEATURING Paolo Tarantino
  • 304 views
  • October 1, 2024
  • 4
02:49

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Real-World Characteristics of NATALEE and monarchE Eligible Populations - A US Electronic Health Records Analysis

FEATURING Paolo Tarantino
  • 241 views
  • September 27, 2024
  • 2
14:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01

FEATURING Paolo Tarantino
  • 1,182 views
  • September 24, 2024
  • 6
12:14

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breast06, postMONARCH, A-BRAVE, Dato/Durva in I-SPY 2.2, and SACI-IO HR+

FEATURING Paolo Tarantino
  • 2,379 views
  • June 21, 2024
  • 16
08:07

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "SACI-IO HR+ Trial - Sacituzumab Govitecan +/- Pembro in Patients With HR+/HER2- mBC"

FEATURING Ana Garrido-Castro
  • 277 views
  • June 13, 2024
  • 2
06:10

Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs With the Checkpoint Inhibitors?"

FEATURING Sara Tolaney
  • 850 views
  • May 22, 2024
  • 8
08:18

Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "Is There a Role for Combining PARP Inhibition With ET and Checkpoint Inhibition in HR+/HER2- mBC?"

FEATURING Sara Tolaney
  • 328 views
  • May 22, 2024
  • 4
05:35

Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Role for IO in Patients With TNBC Who Experience Early Relapse After Neo/Adjuvant Systemic Therapy?"

FEATURING Sara Tolaney
  • 524 views
  • May 21, 2024
  • 7
21:20

Dana-Farber Cancer Institute

Older Adults With Breast Cancer: Research Updates

FEATURING Rachel Freedman
  • 248 views
  • March 1, 2024
  • 2
14:16

Dana-Farber Cancer Institute

Year in Review: Breast Cancer

FEATURING Paolo Tarantino
  • 2,417 views
  • February 1, 2024
  • 18
22:34

Dana-Farber Cancer Institute

What's New in Breast Cancer?

FEATURING Sara Tolaney
  • 1,556 views
  • January 17, 2024
  • 15
17:35

Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HER2CLIMB-02"

FEATURING Paolo Tarantino
  • 1,070 views
  • December 18, 2023
  • 7
17:20

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-756 & BEGONIA"

FEATURING Paolo Tarantino
  • 2,109 views
  • November 3, 2023
  • 12
12:50

Oncology Data Advisor

Expert Perspectives in the Management of TNBC

FEATURING Sara Tolaney
  • 752 views
  • July 9, 2023
  • 7
09:32

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysis - Sacituzumab Govitecan in Pts With HR+/HER2- mBC"

FEATURING Sara Tolaney
  • 705 views
  • June 7, 2023
  • 7
04:28

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant Sacituzumab Govitecan + Pembro vs Pembro ± Capecitabine in TNBC and Residual Disease After Neoadjuvant Therapy and Surgery"

FEATURING Sara Tolaney
  • 2,290 views
  • June 7, 2023
  • 4
12:48

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Association of Tumor-Infiltrating Lymphocytes With Clinicopathologic Characteristics and Prognosis in Young Women With HR+/HER2- BC"

FEATURING Megan Tesch
  • 119 views
  • June 7, 2023
  • 2
11:01

Dana-Farber Cancer Institute

Updates on the Personalized Management of HER2+ eBC for 2023

FEATURING Adrienne Waks
  • 89 views
  • May 31, 2023
14:11

ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 Highlights: Key Studies Including IMPassion031 & ICARUS-BREAST01

FEATURING Paolo Tarantino
  • 768 views
  • May 22, 2023
  • 5
31:07

Dana-Farber Cancer Institute

Supporting Older Adult Cancer Survivors With a Focus on Breast Cancer

FEATURING Rachel Freedman
  • 77 views
  • March 24, 2023
  • 1
39:42

Dana-Farber Cancer Institute

Probing Genome Maintenance Mechanism Through the Lens of BRCA1/2 Synthetic Lethality

FEATURING Daniel Durocher
  • 76 views
  • March 9, 2023
  • 1
33:37

Dana-Farber Cancer Institute

PARPi in Ovarian Cancer: Maximizing Risk/Benefit Ratio

FEATURING Elizabeth Swisher
  • 203 views
  • March 9, 2023
  • 1
33:35

Dana-Farber Cancer Institute

Advances in the Systemic Treatment of BRCA1/2 and PALB2-Associated Breast Cancer

FEATURING Filipa Lynce
  • 101 views
  • March 9, 2023
  • 1
38:50

Dana-Farber Cancer Institute

New Vulnerabilities in BRCAm Cancers

FEATURING Roger Greenberg
  • 44 views
  • March 9, 2023
29:11

Dana-Farber Cancer Institute

Redefining BRCAness and Chemotherapy Response

FEATURING Sharon Cantor
  • 17 views
  • March 9, 2023
36:28

Dana-Farber Cancer Institute

Complexities of Utilizing Immunotherapy in BRCA-Associated Cancers

FEATURING Jennifer Guerriero
  • 123 views
  • March 9, 2023
  • 3
34:05

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute 2022 SABCS Updates on mBC

FEATURING Harold Burstein
  • 192 views
  • March 9, 2023
  • 3
13:32

Dana-Farber Cancer Institute

Impact of DESTINY-Breast04 Data in HER2-Low Breast Cancer: How to Implement in Clinical Practice

FEATURING Paolo Tarantino
  • 962 views
  • February 7, 2023
  • 10
06:04

Dana-Farber Cancer Institute

Updated Exploratory Analysis of the HER2CLIMB Trial for HER2+ mBC With Brain Metastases

FEATURING Nancy Lin
  • 385 views
  • January 25, 2023
06:53

ecancer

SABCS 2022 Primary Results From the POSITIVE Trial: Interruption of ET in Young BC Patients and the Risk of Short-Term Relapse

FEATURING Ann H. Partridge
  • 592 views
  • January 10, 2023
  • 4
05:45

SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC: Final 10-Year Results and HER2DX Analysis

FEATURING Sara Tolaney
  • 1,890 views
  • December 19, 2022
  • 10
02:31

SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rates of Adverse Events of Sacituzumab Govitecan vs. Treatment of Physician’s Choice in HR+/HER2- mBC

FEATURING Sara Tolaney
  • 74 views
  • December 19, 2022
  • 1
16:49

SABCS 2022 Conference Coverage

SABCS 2022 Inflammatory Breast Cancer: A Perfect Storm

FEATURING Filipa Lynce
  • 311 views
  • December 16, 2022
  • 3
14:58

SABCS 2022 Conference Coverage

SABCS 2022 Poster Reviews of Special Populations: Male Breast Cancer

FEATURING Jose Pablo Leone
  • 246 views
  • December 15, 2022
  • 1
14:31

Dana-Farber Cancer Institute

An Overview of Male Breast Cancer

FEATURING Jose Pablo Leone
  • 71 views
  • October 20, 2022
07:56

Dana-Farber Cancer Institute

Aiming at a Tailored Cure for ERBB2+ Metastatic Breast Cancer

FEATURING Paolo Tarantino
  • 166 views
  • January 31, 2022
04:19

Dana-Farber Cancer Institute

ESMO 2021 Update on T-DXd +/- Pertuzumab vs. THP in 1L HER2+ MBC: DESTINY-Breast09

FEATURING Sara Tolaney
  • 329 views
  • September 28, 2021
  • 1
11:30

i3 Health

Optimizing Treatment of MBC: Predictive / Prognostic Biomarkers, Overview of Therapeutic Approaches, AEs Management

FEATURING Sara Tolaney, Ira Bleiweiss, Mikel Ross
  • 30 views
  • August 3, 2021
07:55

Dana-Farber Cancer Institute

2021 ASCO Updates From eMonarcHER on HR+, HER2+, N+, High-Risk eBC: Abemaciclib + Standard Adjuvant ET

FEATURING Sara Tolaney
  • 375 views
  • June 29, 2021
  • 2
09:08

Dana-Farber Cancer Institute

Results from monarcHER Trial on CDK4/6 Inhibitors + ET: Can Abemaciclib + Trastuzumab vs. Trastuzumab + SoC Chemotherapy Improve PFS & ORR in HR+, HER2- Advanced Breast Cancer?

FEATURING Sara Tolaney
  • 548 views
  • June 10, 2020
  • 2
25:16

Dana-Farber Cancer Institute

Endocrine Therapy in Advanced HR+/HER2- Beyond 2020: Addition of CDK4/6 Inhibition Is the SoC in the 1st and 2nd-Line Setting

FEATURING Erica Mayer
  • 1,480 views
  • February 10, 2020
  • 7
07:38

Dana-Farber Cancer Institute

2019 APHINITY Trial Update: Fewer Deaths Seen in Addition of Pertuzumab to Trastuzumab + Chemotherapy in Operable HER2+ Early Breast Cancer

FEATURING Sara Tolaney
  • 1,401 views
  • January 16, 2020
  • 7
07:23

Dana-Farber Cancer Institute

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

FEATURING Sara Tolaney
  • 1,825 views
  • September 24, 2019
  • 8
07:40

Dana-Farber Cancer Institute

Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Breast Cancer

FEATURING Sara Tolaney
  • 5,516 views
  • September 24, 2019
  • 16
07:43

Dana-Farber Cancer Institute

Study of Abemaciclib for Patients with RB-Positive, Triple Negative Metastatic Breast Cancer

FEATURING Shom Goel
  • 918 views
  • April 1, 2019
  • 3